In the present work, we have investigated the role of GluAp, AlaAp, and DPP4 as biomarkers of CSA-AKI, analyzing their diagnostic sensitivity and specificity not only for patients that develop AKI at all stages, but also for patients that develop stage 2 or 3 AKI. This evidence concerns the gene DPP4 and acute kidney injury.